| units | Drug-resistant patients (n = 64) | Drug-responsive patients (n = 41) | Drug-naïve patients (n = 66) | Healthy control (n = 40) | P |
---|---|---|---|---|---|---|
CD3+CD19− | %PBMCs | 70.7 ± 6.6 | 72.2 ± 8.0 | 70.0 ± 8.6 | 69.4 ± 5.7 | 0.30 |
CD3−CD19+ | %PBMCs | 13.8 ± 4.5 | 12.0 ± 4.8 | 14.1 ± 6.4 | 13.1 ± 2.8 | 0.15 |
CD3−CD16+56+ | %PBMCs | 14.1 ± 5.2 | 13.9 ± 7.3 | 13.7 ± 7.3 | 12.3 ± 3.7 | 0.35 |
CD3+CD4+ | %PBMCs | 39.5 ± 5.9 | 40.1 ± 7.3 | 40.6 ± 7.9 | 37.7 ± 3.7 | 0.11 |
CD3+CD8+ | %PBMCs | 25.2 ± 6.5 | 26.1 ± 7.8 | 24.5 ± 9.3 | 23.9 ± 4.5 | 0.37 |
CD4+/CD8+ |  | 1.7 ± 0.7 | 1.7 ± 0.6 | 1.9 ± 1.0 | 1.8 ± 0.5 | 0.61 |
CD3+CD4−CD8− | %PBMCs | 6.9 ± 2.9 | 6.9 ± 4.3 | 6.1 ± 3.8 | 6.0 ± 3.2 | 0.15 |
CD4+CD25high | %PBMCs | 2.3 ± 1.4 | 2.7 ± 1.4 | 2.7 ± 1.3 | 2.5 ± 1.2 | 0.28 |